SABS Stock Analysis: Buy, Sell, or Hold?
SABS - SAB Biotherapeutics, Inc. Common Stock
$3.78
0.08 (2.16%)
â˛
5d:
+2.16%
30d:
+5.59%
90d:
-0.79%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When SABS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SABS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SABS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SABS is currently trading at $3.78, which is considered slightly high relative to its 30-day fair value range of $3.54 to $3.80.
Technical Outlook: Technically, SABS is showing sideways momentum. The price is approaching resistance at $3.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.64 (+207.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SABS is showing sideways momentum. The price is approaching resistance at $3.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.64 (+207.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.54 -
$3.80
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (51/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 207.8% below Wall St target ($11.64)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.54 -
$3.80
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.66
Resistance Level
$3.89
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.96
Wall Street Target
$11.64
(+207.8%)
Revenue Growth (YoY)
-62.4%
Earnings Growth (YoY)
-60.0%
Share & Embed Analysis
Last updated: August 24, 2026 5:27 AM ET
Data refreshes hourly during market hours. Next update: 6:27 AM
Data refreshes hourly during market hours. Next update: 6:27 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SABS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
